Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyAvMed Adstiladrin Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Adstiladrin (nadofaragene firadenovec-vncg) prior authorization — Non‑muscle invasive bladder cancer

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Requirements and clinical criteria for prior authorization of Adstiladrin (J9029) for treatment of non‑muscle invasive bladder cancer in AvMed members; intended for prescribing providers and facility staff submitting PA/step-edit requests.

    Policy Summary
    PayerAvMed
    PolicyAdstiladrin (nadofaragene firadenovec-vncg) prior authorization
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionPrescriber must complete and hand-sign the prior authorization form and provide required clinical documentation supporting the criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4 dosesmaximum total treatments (over one year)
    1 dose / 3 mobilling frequency / max units
    3 monthsinitial approval length
    6 monthsrenewal approval length

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18+
    minimum patient age

    Coverage Criteria for Adstiladrin (nadofaragene firadenovec-vncg)

    Initial Authorization

    Covered when ALL of the following are met for initial authorization:

    Initial Authorization Criteria: Member is 18 years of age or older; provider requesting therapy is an oncologist or a urologist with consult/specialty in oncology; diagnosis of non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, with workup documenting absence of extra-vesical, muscle-invasive (T2-T4), or metastatic urothelial carcinoma; member has undergone transurethral resection of bladder tumor (TURBT) to remove all resectable disease (Ta and T1 components); member has high-risk disease unresponsive to an adequate trial of BCG evidenced by ONE of: initial complete response to BCG with relapse of CIS within 12 months of last intravesical treatment; high-grade recurrence within 12 months after BCG initiation; or relapse with high-grade Ta/T1 NMIBC within 6 months of last intravesical BCG; member has had adequate BCG therapy defined as two prior courses within a 12-month period with either (a) at least five of six induction BCG instillations plus at least two of three maintenance instillations, or (b) at least two of six instillations of a second induction course; if high-grade Ta/T1 without CIS, relapse must be documented within 6 months of last BCG exposure; medication will be used as a single agent via intravesical instillation only; member has no hypersensitivity to interferon alfa.

    All lines must be met and supported by documentation.

    Reauthorization

    Covered when ALL of the following are met for reauthorization:

    Reauthorization Criteria: Member continues to meet applicable initial authorization criteria; member has experienced disease response defined as stabilization of disease or decrease in size of tumor or tumor spread; member has experienced an absence of unacceptable toxicity from the drug (e.g., disseminated adenovirus infection); for first renewal: member has a complete response (CR) to initial therapy at 3 months defined as negative cystoscopy (with TURBT/biopsies as applicable) and urine cytology; for subsequent renewals: member has not experienced a high-grade or CIS recurrence.

    To support each line checked, all documentation including lab results, diagnostics, and/or chart notes must be provided or request may be denied.

    Members must have documentation demonstrating the absence of extra‑vesical disease, muscle‑invasive disease (T2–T4), or metastatic urothelial carcinoma. Approval requires recorded workup or evaluation showing that disease is confined to the bladder (no involvement of the urethra, ureter, renal pelvis, or distant sites) and specifically that muscle‑invasive (T2–T4) or metastatic disease is NOT present.

    Use of manufacturer or office samples to start Adstiladrin does not meet preauthorization or step‑edit requirements and will not be accepted as evidence that therapy was initiated. Prior therapies and treatment history will be verified through pharmacy paid claims or submitted chart notes; therefore, sample use cannot substitute for required documentation when requesting authorization.

    Coding and Billing Information

    Covered HCPCS CodesHCPCSCovered
    J9029Adstiladrin (nadofaragene firadenovec-vncg)
    NDCNDC
    55566-1050-01NDC for Adstiladrin 20 mL single-dose vial
    inv-07: Maximum vials per treatment
    Maximum vials per treatment4 vials per treatment (1 treatment = 4 vials); dosing limited to 4 vials every three months for up to four doses total
    Treatment course totalMaximum of 4 total treatments (over one year)
    Vial strength / presentationAdstiladrin suspension 3 × 10^11 viral particles (vp)/mL, 20 mL single‑dose vial (NDC 55566-1050-01)
    inv-08: Billing unit frequency
    Billing unit frequency1 billable unit (1 dose) every 3 months
    Maximum billable dosesUp to 4 doses total (one dose every 3 months)

    Provider Actions and Prior Authorization Requirements

    Prior Authorization

    Prior authorization required (J9029) — prescriber must sign PA form

    Prior authorization is required for Adstiladrin (nadofaragene firadenovec-vncg), HCPCS J9029. The prescribing provider must complete and sign the medical prior authorization/step-edit request form (hand-signed; preprinted stamps not valid) and supply clinical documentation that supports the coverage criteria.

    • Drug Requested: Adstiladrin (J9029)
    • Prescribing physician must sign and clearly print name on the PA form (preprinted stamps not valid)
    Step Therapy

    Samples not acceptable to meet PA/step-edit

    Use of samples to initiate therapy will not satisfy preauthorization or step-edit requirements and is not acceptable documentation of prior therapy; prior treatments will be verified via pharmacy paid claims or submitted chart notes.

    • Samples cannot be used to meet therapy initiation or step-edit criteria

    Definitions

    inv-15: Adequate BCG therapy
    Definition (Adequate BCG therapy)Two previous courses of BCG within a 12‑month period, defined as either: (a) at least 5 of 6 induction instillations plus at least 2 of 3 maintenance instillations, OR (b) at least 2 of 6 instillations of a second induction course.
    TimeframePrior BCG courses must occur within a 12‑month period
    Acceptable exposure examples5/6 induction + 2/3 maintenance OR 2/6 of a second induction course satisfy adequate exposure
    inv-16: BCG-unresponsive / high-risk disease
    BCG‑unresponsive / high‑risk disease definitionIncludes patients with initial complete response to BCG who relapse with CIS within 12 months of last intravesical treatment, OR high‑grade recurrence within 12 months after BCG initiation, OR relapse with high‑grade Ta/T1 NMIBC within 6 months of last intravesical BCG treatment.
    CIS relapse timing

    Background

    Adstiladrin (nadofaragene firadenovec‑vncg) is an intravesical gene therapy indicated for treatment of non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The policy expects prior transurethral resection of bladder tumor (TURBT) to remove all resectable disease and requires that the medication be used as a single‑agent intravesical instillation. Approval is limited to adults (age ≥18 years) and excludes members with hypersensitivity to interferon alfa.

    Policy Summary
    PayerAvMed
    PolicyAdstiladrin (nadofaragene firadenovec-vncg) prior authorization
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionPrescriber must complete and hand-sign the prior authorization form and provide required clinical documentation supporting the criteria.
    SourceLink
    On This Page
    Coverage Criteria for Adstiladrin (nadofaragene firadenovec-vncg)Coding and Billing InformationProvider Actions and Prior Authorization RequirementsDefinitionsBackground
    Unit definition1 treatment equals 4 vials; billing unit = 1 dose (per treatment interval)
  1. Previous therapies verified through pharmacy paid claims or chart notes
  2. Documentation Required

    Required documentation to support PA

    Provide the completed PA form with the prescriber's hand signature and contact information, member demographics, diagnosis, and supporting clinical documentation including workup demonstrating absence of extra‑vesical, muscle‑invasive, or metastatic disease; TURBT operative notes; BCG treatment history and response; and site/contact information for administration.

    • Prescriber signature (hand-signed; preprinted stamps not valid)
    • Member demographics and diagnosis (NMIBC with CIS) and documentation that excludes extra‑vesical/muscle‑invasive/metastatic disease
    • TURBT operative notes and BCG treatment history/response
    • Location/NPI/DEA of administering site or specialty pharmacy information
    Denial Risk

    Incomplete or illegible submissions risk delay/denial

    Incomplete, incorrect, or illegible information on the PA request can delay review or result in denial of authorization; ensure all required fields and legible contact information are provided.

    • Ensure form is complete, correct, and legible to avoid delays or denial
    Denial Risk

    Insufficient clinical documentation may cause denial

    Failure to provide required supporting clinical documentation — such as lab results, diagnostic studies, chart notes, cystoscopy/TURBT/biopsy reports, and documentation of prior BCG therapy and response — may result in denial of the request.

    • Include lab results, diagnostics, and chart notes as indicated for each criterion checked
    • Provide cystoscopy and urine cytology results for renewals and TURBT/biopsy operative reports
    • Document prior BCG courses and response per the policy definition
    Relapse with carcinoma in situ (CIS) within 12 months of last intravesical BCG treatment
    High‑grade recurrence timingHigh‑grade recurrence within 12 months after BCG was initiated
    High‑grade Ta/T1 without CISIf high‑grade Ta/T1 without CIS, relapse must be documented within 6 months of last BCG exposure